Serina Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Serina Therapeutics, Inc. (SER) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-03-25
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-09-30 was 0.00%.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2020-09-30 was 0.00%.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2020-06-30 was 0.00%.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2019-09-30 was 0.00%.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-03-25 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-25 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-12 | 0.00% 10-Q · filed 2024-11-12 | ||
| 2023-12-31 | 0.00% 10-K · filed 2025-03-24 | |||
| 2022-12-31 | 0.00% 10-K · filed 2023-03-31 | |||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-31 | |||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-29 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2020-11-16 | 0.00% 10-Q · filed 2020-11-16 | ||
| 2020-06-30 | 0.00% 10-Q · filed 2020-08-14 | 0.00% 10-Q · filed 2020-08-14 | ||
| 2019-12-31 | 0.00% 10-K · filed 2021-03-31 | |||
| 2019-09-30 | 0.00% 10-Q · filed 2020-11-16 | 0.00% 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | 0.00% 10-Q · filed 2020-08-14 | 0.00% 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | 0.00% 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | 0.00% 10-K/A · filed 2020-03-31 | |||
| 2018-09-30 | 0.00% 10-Q · filed 2019-11-14 | 0.00% 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | 0.00% 10-Q · filed 2019-08-14 | 0.00% 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | 0.00% 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |